RapidAI Revolutionizes Neurocritical Care With New FDA-Cleared Module

RapidAI, a world leader in AI and technology workflow solutions for life-threatening neurovascular, trauma, cardiac, and vascular conditions, has announced that its AI-powered module, Rapid SDH, has been approved by the FDA. This is a big step forward. This new idea is meant to quickly find and report both short-term and long-term subdural hematomas, meeting a very important need in neurocritical care.

RapidAI's full set of hemorrhagic and trauma care AI solutions, such as Rapid ICH and Rapid Hyperdensity, are very important for helping frontline assessment teams make decisions faster and get patients better faster. The urgency of such solutions cannot be overstated, especially with the prediction of an 80% rise in subdural hematoma cases in the United States by 2040 and fatality rates ranging from 40 to 60%, compounded by shortages in the neurosurgical workforce.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

With the help of artificial intelligence and hundreds of images of patients, Rapid SDH helps neurocritical care teams diagnose hemispheric subdural hemorrhages at a speed and accuracy that has never been seen before. Rapid SDH's ability to send results to the entire trauma team across hospital systems or treatment networks in under a minute through its sophisticated mobile app further improves the speed of diagnosis.

One important thing about Rapid SDH is that it is the only hemorrhagic and trauma package that can find hemispheric SDH, intracerebral hemorrhage (ICH), and hyperdensity. This lets doctors get a better picture of the patient. The module boasts an industry-leading positive predictive value (PPV) of 99%, with a sensitivity of 93% and a specificity of 99% for suspected acute and chronic hemispheric subdural hematomas greater than 1 mL.

The expeditious nature of Rapid SDH's results is a game-changer, notifying clinicians in one minute or less. This swift dissemination of information empowers clinicians to make faster and more informed decisions regarding the transfer and treatment of patients with traumatic brain injuries or hemorrhagic strokes.

Patients with subdural hematomas can now seamlessly navigate treatment and transfer decisions through automatic notifications delivered via the Rapid mobile app, PACS, and email.

The CEO of RapidAI, Amit Phadnis, was excited about the FDA approval. He said, "The FDA's clearance of Rapid SDH significantly enhances our expanding range of hemorrhagic and trauma care solutions at this crucial time of rapidly growing patient numbers, clinician shortages, and better treatment options." He emphasized the company's commitment to leveraging deep AI capabilities to deliver comprehensive clinical solutions that provide care teams with essential insights to evaluate patients, streamline decision-making, and expedite care for this prevalent and perilous disease.

The integration of cutting-edge AI technology not only enhances diagnostic speed and accuracy but also empowers healthcare professionals to navigate the complex landscape of traumatic brain injuries with unprecedented efficiency.